Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
The industry rank for Tong Ren Tang Technologies Co's Net-Net Working Capital or its related term are showing as below:
TGRNF's Price-to-Net-Net-Working-Capital is ranked better than 79.61% of 407
companies
in the Drug Manufacturers industry
Industry Median: 8.41
vs TGRNF: 3.09
Tong Ren Tang Technologies Co (OTCPK:TGRNF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Tong Ren Tang Technologies Co Net-Net Working Capital Related Terms
Tong Ren Tang Technologies Co Net-Net Working Capital Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tong Ren Tang Technologies Co Net-Net Working Capital Chart
TGRNF vs LLY, JNJ, ABBV: Net-Net Working Capital Comparison
For the Drug Manufacturers - General subindustry, Tong Ren Tang Technologies Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tong Ren Tang Technologies Co Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tong Ren Tang Technologies Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Tong Ren Tang Technologies Co's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.14 mean?
Tong Ren Tang Technologies Co (TGRNF) has a Net-Net Working Capital of $0.14 as of Dec. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Tong Ren Tang Technologies Co According to the industry distribution chart, Tong Ren Tang Technologies Co ranks #83 out of 407 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Tong Ren Tang Technologies Co's Net-Net Working Capital too high?
Tong Ren Tang Technologies Co's current Net-Net Working Capital is $0.14. The Drug Manufacturers industry median Net-Net Working Capital is 8.41. Tong Ren Tang Technologies Co's value of $0.14 is 98.3% below this industry median. Based on the distribution chart, Tong Ren Tang Technologies Co ranks #83 out of 407 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tong Ren Tang Technologies Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Tong Ren Tang Technologies Co's Net-Net Working Capital compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Tong Ren Tang Technologies Co ranks #83 out of 407 companies for Net-Net Working Capital. This places Tong Ren Tang Technologies Co in the top 20% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 8.41. Tong Ren Tang Technologies Co's value of $0.14 is 98.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 8.41, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tong Ren Tang Technologies Co's current Net-Net Working Capital of $0.14 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Tong Ren Tang Technologies Co For the Drug Manufacturers industry, the median Net-Net Working Capital is 8.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tong Ren Tang Technologies Co's current Net-Net Working Capital is $0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tong Ren Tang Technologies Co stock overvalued right now?
Tong Ren Tang Technologies Co (TGRNF) has a current Net-Net Working Capital of $0.14. The stock's GF Value™ is $0.81, compared to a current price of $0.49 — trading 38.9% below its estimated fair value. The current Net-Net Working Capital is $0.14 and 98.3% below the Drug Manufacturers industry median of 8.41. Tong Ren Tang Technologies Co's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Tong Ren Tang Technologies Co (TGRNF), the current Net-Net Working Capital is $0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tong Ren Tang Technologies Co (TGRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co stock appears to be undervalued.
The current stock price of $0.49 is trading 38.9% below its estimated GF Value™ of $0.81.
Key valuation signals for TGRNF:
Net-Net Working Capital: $0.14
GF Value™: $0.81 vs. price of $0.49 (38.9% below fair value)
Industry Position: 98.3% below the Drug Manufacturers median (#83 of 407)
No single metric tells the full story. See the TGRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tong Ren Tang Technologies Co Ltd is engaged in the production and distribution of Chinese medicine and predominantly operates in Mainland China and Hong Kong. The operating segments derive their revenue predominantly from the manufacture and sale of Chinese medicine of the company in Mainland China and Tong Ren Tang Chinese Medicine and its subsidiaries engaged in manufacturing, retail, and wholesale of Chinese medicine products and healthcare products, and provision of Chinese medical consultation and treatments outside Mainland China and wholesale of healthcare products in Mainland China.
78GF Score
Get the complete analysis for TGRNF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGRNF has been successfully added to your 
